ReviewNeuro-oncology2025
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Abstract readReview
In one paragraph
Review in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies.Cancer letters · 2026Article
- EDNRB-dependent endothelin signaling reduces proliferation and promotes proneural-to-mesenchymal transition in gliomas.Molecular oncology · 2026Article
- Perampanel as add-on in high-grade glioma-related epilepsy: Seizure control and QoL in a prospective, multicenter, real-world 6-month follow-up study.Epilepsia open · 2026Observational
- Article
- First-in-human phase I study of hypoxia-targetingESMO open · 2026Article
- Contemporary surgical strategies for resection of intracranial gliomas.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Laser Interstitial Thermal Therapy as Surgical Approach for Unresectable Glioblastoma: Hope is on the Horizon?The Lancet regional health. Europe · 2026Article
- Predictive value of apparent diffusion coefficient, plasma levels of placental growth factor and glial fibrillary acidic protein, and their combinations for patients with recurrent glioblastoma.Discover oncology · 2026Article
- Prolactin-Releasing Hormone Receptor (PRLHR) enhances radiosensitivity and exacerbates DNA damage in glioblastoma post-irradiation by inhibiting Y-box-binding protein-1 (YBX1) nuclear translocation: a novel perspective on precision radiotherapy.Molecular biomedicine · 2026Article
- Rewriting microenvironment immunity in glioblastoma.Molecular therapy. Oncology · 2026Article
- Survival after hypofractionated radiation versus standard radiation in glioblastoma by MGMT promoter methylation status and age: an analysis of the national cancer database.Journal of neuro-oncology · 2026Article
- Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer Immunotherapy.Cancers · 2026Article
- Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.Molecular biomedicine · 2026Review
- A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Phosphorylated mTOR immunohistochemistry-guided use of temsirolimus in recurrent IDH-wildtype glioblastoma: a real-world retrospective series.Journal of cancer research and clinical oncology · 2026Article
- Recent Advances in Targeted Therapies for Adult Gliomas.Current neurology and neuroscience reports · 2026Review
- Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens.Diagnostics (Basel, Switzerland) · 2026Article
- Current Pharmacotherapeutic Strategies in Diffuse Gliomas: Focus on Glioblastoma, IDH-Wildtype, and Emerging Targeted Therapies for IDH-Mutant Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.Frontiers in pharmacology · 2026Article
- A spatiotemporal state-inference framework for adaptive immunotherapy in glioblastoma.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Patrick Y WenDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Michael WellerDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1748-174X
Eudocia Q LeeDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Mehdi TouatService de Neuro-oncologie, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.ORCID 0000-0002-5910-7799
Mustafa KhasrawThe Preston Robert Tisch Brain Tumor Center, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-3249-9849
Rifaquat RahmanDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
Michael PlattenDepartment of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University and German Cancer Research Center, DKTK, Heidelberg, Germany.ORCID 0000-0002-4746-887X
Michael LimDepartment of Neurosurgery, Stanford University, Stanford, California, USA.
Frank WinklerNational Center for Tumor Diseases, Heidelberg, Germany.ORCID 0000-0003-4892-6104
Craig HorbinskiDepartment of Pathology, Northwestern University, Chicago, Illinois, USA.
Roel G W VerhaakDepartment of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-2773-0436
Raymond Y HuangDivision of Neuroradiology, Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Manmeet S AhluwaliaDivision of Medical Oncology, Baptist Health Miami Cancer Institute, Florida International University, Miami, Florida, USA.
Nathalie L AlbertDepartment of Nuclear Medicine, LMU University Hospital, Ludwig Maximilians University Munich, Munich, Germany.ORCID 0000-0003-0953-7624
Joerg-Christian TonnDepartment of Neurosurgery Klinikum Ludwig Maximilians University Munich, Munich, Germany.ORCID 0009-0004-1756-423X
David SchiffDivision of Neuro-Oncology, Department of Neurology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0002-1896-2502
Jill S Barnholtz-SloanCenter for Biomedical Informatics and Information Technology and Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-6190-9304
Quinn OstromDepartment of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
Kenneth D AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Tracy T BatchelorDepartment of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Ranjit S BindraDepartments of Therapeutic Radiology, Pathology, and Neurosugery, Yale Medical School, New Haven, Connecticut, USA.
E Antonio ChioccaDepartment of Neurosurgery, Mass General Brigham, Boston, Massachusetts, USA.
Timothy F CloughesyUniversity of California, Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-8656-7483
John F DeGrootDepartment of Neurology and Neurosurgery, University of California, San Francisco, San Francisco, California, USA.
Pim FrenchDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0002-0668-9529
Evanthia GalanisDepartment of Oncology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-8014-786X
Norbert GalldiksCenter of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.ORCID 0000-0002-2485-1796
Mark R GilbertNational Institutes of Health, Bethesda, Maryland, USA.
Monika E HegiNeuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Andrew B LassmanDivision of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, and Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian, New York, New York, USA.
Emilie Le RhunDepartment of Medical Oncology and Hematology, and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
Minesh P MehtaDepartment of Radiation Oncology, Florida International University, Baptist Health, Miami Cancer Institute, Miami, Florida, USA.
Ingo K MellinghoffDepartment of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-4347-8149
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza and IRCCS Neuromed, Pozzilli, Italy.
Patrick RothDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID 0000-0003-3897-214X
Marc SansonService de Neuro-oncologie, Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, Paris Brain Institute, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.ORCID 0000-0002-1813-8476
Martin J B Taphoorn AndreasDepartment of Neurology, Leiden University Medical Center, The Netherlands.
von Deimling Tobias WeissDepartment of Neuropathology, University Hospital Heidelberg, and CCU Neuropathology, German Cancer Center (DKFZ), Heidelberg, Germany.
Wolfgang WickDepartment of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.ORCID 0000-0002-6171-634X
Gelareh ZadehNeurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
David A ReardonDepartment of Neurologic Surgery, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.ORCID 0000-0001-6674-0157
Susan M ChangDana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Susan C ShortDepartment of Neurological Surgery, University of California, San Francisco, San Francisco California, USA.
Martin J van den BentDepartment of Oncology, St James's University Hospital and University of Leeds, Leeds, UK.
Matthias PreusserDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Funding
The Patient-Reported Outcomes, Community-Engagement and Language (PRO-CEL) CoreP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · 1985 to 2025
$88.4MNCI NIH HHS P30 CA008748
Abstract
Glioblastoma is the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. In 2021, the World Health Organization updated the classification of Central Nervous System (CNS) tumors to restrict glioblastomas to isocitrate dehydrogenase-wildtype (IDHwt) tumors, improving understanding of the prognosis and optimal therapy for these tumors. This revision also enables more homogeneous populations of patients to be enrolled in clinical trials, facilitating the evaluation of novel therapies. In this updated consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of patients with glioblastoma is discussed. In addition, novel therapies such as immunotherapies, viral therapies, targeted molecular therapies, theranostics, and antibody-drug conjugates will be reviewed, as well as the current challenges and future directions for research.
Indexed as
Brain NeoplasmsGlioblastomaAdultConsensus Statements as TopicDisease ManagementHumansMedical OncologySocieties, MedicalEANOGlioblastomanovel therapiesSNOstandard therapies
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.